Still no announcement of a financing ~17 days after the release of the financials. A small financing should have been announced by now under competent management. There are also only 12 more business days remaining until BTI may be out of money without further developments.

With more than one party said interested in the cancer assets this long after the cancer assets were put on the block is a deal about to happen? With two parties said interested if one party isn't willing to act there is still another party that can act. If each party has a 50% chance of closing a deal chances are a deal will be closed by one or the other party. With the J&J option deal signed, the Daiichi collaboration, and the Chiesi deal world class interest has been generated. xB3-001 was BTI's  prized asset under three management teams. Sunnybrooke has demonstrated certain success delivering Herceptin across the blood-brain barrier with focused-ultrasound. Other science supports Herceptin's efficacy in the brain. Denali has also pursued Herceptin. Rathjen has compared xB3 to Denali's platform. BTI has hired a US investment banker and is seeking a NASDAQ listing. Cresence accepted BTI shares at a ratio placing substantial value on xB3 relative to their trial-ready technology and Cresence insiders will continue with BTI. Certain shares Cresence received were locked up.

A deal for the cancer assets could provide substantial validation, significan upfront money, and material milestone payments and potential royalties and support a financing at a better share price than present. It could also support a NASDAQ listing.